Dermata regains Nasdaq minimum bid price compliance; delisting risk resolved

Dermata Therapeutics, Inc.

Received Nasdaq notice on June 4, 2024 that company is in compliance with $1.00 minimum bid price requirement.
Previously failed to comply in Nov 2023 and received a 180-day extension through Nov 11, 2024.
Compliance regained ahead of extension deadline; matter closed.

item 8.01

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-007369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.